Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pitavastatin vs Pitavastatin/Fenofibrate in Complex-dyslipidemia
NCT03618797Phase 3Completed
- Sponsor
- Hanlim Pharm
- Start
- Nov 2015
- Primary completion
- Jan 2018
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of fenofibrate and pitavastatin in dyslipidemia (2 arms), sponsored by Hanlim Pharm. Primary endpoint: Mean percentage change of Non-HDL Cholesterol at 8 weeks. Started Nov 2015; status: completed.
02
Drugs
fenofibratepitavastatin
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT03618797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03618797.